

Javier Martin-Broto

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1125258/javier-martin-broto-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

143
papers

6,001
citations

39
h-index

75
g-index

151
ext. papers

7,786
ext. citations

6.3
avg, IF

5.49
L-index

#	Paper	IF	Citations
143	Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. <i>New England Journal of Medicine</i> , 2009 , 361, 766-76	59.2	387
142	Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. <i>Lancet Oncology, The</i> , 2009 , 10, 1045-52	21.7	352
141	Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv51-iv67	10.3	316
140	Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). <i>Journal of Clinical Oncology</i> , 2005 , 23, 6190-8	2.2	291
139	Building a global consensus approach to chordoma: a position paper from the medical and patient community. <i>Lancet Oncology, The</i> , 2015 , 16, e71-83	21.7	269
138	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology, The</i> , 2017 , 18, 812-822	21.7	259
137	Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv79-iv95	10.3	223
136	Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv68-iv78	10.3	207
135	Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2528-33	2.2	187
134	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). <i>Annals of Oncology</i> , 2017 , 28, 2399-2408	10.3	174
133	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 478-487	40	148
132	Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. <i>Modern Pathology</i> , 2008 , 21, 476-84	9.8	148
131	Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. <i>Clinical Cancer Research</i> , 2012 , 18, 4458-64	12.9	143
130	Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii49-55	10.3	132
129	Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2012 , 30, 850-6	2.2	128
128	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. <i>Annals of Oncology</i> , 2017 , 28, 1230-1242	10.3	108
127	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4276-83	2.2	102

126	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1266-1276	27.4	91
125	A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. <i>Cancer</i> , 2005 , 104, 1706-12	6.4	79
124	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , 2012 , 118, 5857-66	6.4	73
123	GEIS guidelines for gastrointestinal sarcomas (GIST). <i>Cancer Treatment Reviews</i> , 2017 , 55, 107-119	14.4	64
122	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Annals of Oncology</i> , 2016 , 27, 2283-2288	10.3	64
121	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii100-9	10.3	58
120	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2019 , 20, 134-144	21.7	58
119	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2178-2186	2.2	57
118	Giant cell tumour of bone: new treatments in development. <i>Clinical and Translational Oncology</i> , 2015 , 17, 419-30	3.6	57
117	Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. <i>Annals of Oncology</i> , 2013 , 24, 817-23	10.3	55
116	Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1893-8	2.2	54
115	Adjuvant therapy in primary GIST: state-of-the-art. <i>Annals of Oncology</i> , 2012 , 23, 2776-2781	10.3	54
114	Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). <i>Annals of Oncology</i> , 1998 , 9, 871-6	10.3	51
113	Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. <i>Annals of Oncology</i> , 2010 , 21, 1552-1557	10.3	50
112	Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2294-302	2.2	50
111	Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. <i>European Journal of Cancer</i> , 2015 , 51, 1611-7	7.5	48
110	Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021 , 32, 1348-1365	10.3	48
109	Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. <i>Sarcoma</i> , 2012 , 2012, 740279	3.1	47

108	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. <i>JAMA Oncology</i> , 2018 , 4, e180219	13.4	46
107	Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study. <i>Acta Oncologica</i> , 2014 , 53, 1173-9	3.2	45
106	Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3628-34	2.2	42
105	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018 , 23, 62-70	5.7	42
104	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. <i>Annals of Oncology</i> , 2020 , 31, 1506-1517	10.3	39
103	Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). <i>Annals of Surgical Oncology</i> , 2015 , 22, 2948-57	3.1	35
102	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1252-1262	21.7	34
101	Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas. <i>PLoS ONE</i> , 2012 , 7, e37735	3.7	34
100	Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). <i>Annals of Oncology</i> , 2017 , 28, 2994-2999	10.3	33
99	GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 883-98	3.5	33
98	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020 , 126, 2637-2647	6.4	31
97	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. <i>European Journal of Cancer</i> , 2018 , 93, 28-36	7.5	31
96	Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 133-46	3.5	31
95	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial 2020 , 8,		29
94	Trabectedin and Radiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. <i>EClinicalMedicine</i> , 2019 , 9, 35-43	11.3	28
93	Anal canal duplication: a retrospective analysis of 12 cases from two European pediatric surgical departments. <i>Pediatric Surgery International</i> , 2006 , 22, 967-73	2.1	28
92	Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). <i>Sarcoma</i> , 2005 , 9, 127-32	3.1	27
91	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 456-466	21.7	25

90	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. <i>British Journal of Cancer</i> , 2017 , 117, 1278-1285	8.7	25
89	Clinical implications of KIT and PDGFRA genotyping in GIST. <i>Clinical and Translational Oncology</i> , 2010 , 12, 670-6	3.6	25
88	Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). <i>Journal of Neuro-Oncology</i> , 2004 , 70, 359-69	4.8	25
87	SEOM Clinical Guideline of management of soft-tissue sarcoma (2016). <i>Clinical and Translational Oncology</i> , 2016 , 18, 1213-1220	3.6	24
86	Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). <i>Oncologist</i> , 2019 , 24, e338-e346	5.7	24
85	Malignant bone tumors (other than Ewing [®]): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 1113-1131	3.5	23
84	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. <i>Oncologist</i> , 2015 , 20, 823-30	5.7	23
83	International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol. <i>Trials</i> , 2020 , 21, 96	2.8	23
82	MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 249-59	6.1	23
81	Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. <i>BMC Cancer</i> , 2020 , 20, 99	4.8	21
80	RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas. <i>Cancer Investigation</i> , 2015 , 33, 440-50	2.1	19
79	Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein. <i>Journal of Nutritional Biochemistry</i> , 2014 , 25, 429-38	6.3	19
78	Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). <i>Oncotarget</i> , 2016 , 7, 67033-67046	5.9	19
77	Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 535-541	13.4	17
76	Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5239-5249	12.9	16
75	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , 2020 , 155, e200397	5.4	14
74	A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons. <i>Cancers</i> , 2021 , 13,	6.6	14
73	Options for treating different soft tissue sarcoma subtypes. <i>Future Oncology</i> , 2018 , 14, 25-49	3.6	14

72	sarcoma Full-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial. <i>Annals of Oncology</i> , 2016 , <i>27</i> , vi587	10.3	13
71	Yondelis [®] (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action. <i>European Journal of Pharmacology</i> , 2011 , <i>658</i> , 57-64	5.3	13
70	SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016). <i>Clinical and Translational Oncology</i> , 2016 , <i>18</i> , 1221-1228	3.6	13
69	GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). <i>British Journal of Cancer</i> , 2017 , <i>117</i> , 767-774	8.7	12
68	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. <i>Oncologist</i> , 2019 , <i>24</i> , e536-e541	5.7	12
67	Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study. <i>Investigational New Drugs</i> , 2018 , <i>36</i> , 468-475	4.3	11
66	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021 , <i>127</i> , 2934-2942	6.4	11
65	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021 , <i>6</i> , 100170	6	11
64	Disruption of TCF/ β Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells. <i>Molecular Cancer Therapeutics</i> , 2017 , <i>16</i> , 1166-1176	6.1	10
63	Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis. <i>Clinical and Translational Oncology</i> , 2017 , <i>19</i> , 536-545	3.6	10
62	New drugs in gastrointestinal stromal tumors. <i>Current Opinion in Oncology</i> , 2020 , <i>32</i> , 314-320	4.2	10
61	SEOM clinical guidelines for the management of adult soft tissue sarcomas. <i>Clinical and Translational Oncology</i> , 2012 , <i>14</i> , 541-4	3.6	10
60	The importance of treating by histological subtype in advanced soft tissue sarcoma. <i>Future Oncology</i> , 2017 , <i>13</i> , 23-31	3.6	9
59	Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2020 , <i>26</i> , 5801-5808	3.9	9
58	Trabectedin clinical cases: use according to indication in diverse clinical scenarios. <i>Future Oncology</i> , 2015 , <i>11</i> , 15-24	3.6	9
57	Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma. <i>PLoS ONE</i> , 2016 , <i>11</i> , e0155946	3.7	9
56	Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study. <i>European Journal of Surgical Oncology</i> , 2021 , <i>47</i> , 2166-2172	3.6	9
55	Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. <i>Cancers</i> , 2020 , <i>12</i> ,	6.6	8

54	Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. <i>Investigational New Drugs</i> , 2014 , 32, 287-94	4.3	8
53	A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer. <i>Clinical and Translational Oncology</i> , 2005 , 7, 66-73	3.6	8
52	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021 , 10, 2645-2659	4.8	8
51	Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: potential role of a new sex- and age-adjusted reference value. <i>International Journal of Laboratory Hematology</i> , 2010 , 32, 582-9	2.5	7
50	Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 132-141	6.1	7
49	Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS). <i>Sarcoma</i> , 2006 , 2006, 26986	3.1	6
48	Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol. <i>Cancers</i> , 2020 , 13,	6.6	6
47	Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 195	2.1	6
46	Impact of Wnt/ECatenin Inhibition on Cell Proliferation through Downregulation in Soft Tissue Sarcomas. <i>Cancers</i> , 2020 , 12,	6.6	6
45	SEOM Clinical Guideline of management of soft-tissue sarcoma (2020). <i>Clinical and Translational Oncology</i> , 2021 , 23, 922-930	3.6	6
44	Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. <i>Targeted Oncology</i> , 2018 , 13, 81-87	5	6
43	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020 , 5,	6	5
42	Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study. <i>PLoS ONE</i> , 2015 , 10, e0124239	3.7	5
41	Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS). <i>Annals of Oncology</i> , 2017 , 28, 103-111	10.3	5
40	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021 , 17, 2923-2939	3.6	5
39	Cancer Stem Cells in Soft-Tissue Sarcomas. <i>Cells</i> , 2020 , 9,	7.9	4
38	Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 15-28	3.5	4
37	SEOM guidelines for gastrointestinal stromal sarcomas (GIST). <i>Clinical and Translational Oncology</i> , 2012 , 14, 536-40	3.6	4

36	Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor. <i>Current Opinion in Oncology</i> , 2016 , 28, 338-44	4.2	4
35	Sunitinib Exerts Immunomodulatory Activity on Sarcomas Dendritic Cells and Synergizes With PD-1 Blockade. <i>Frontiers in Immunology</i> , 2021 , 12, 577766	8.4	4
34	,, and as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study. <i>Cancers</i> , 2020 , 12,	6.6	3
33	Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: a study of the Spanish Group for Research on Sarcomas (GEIS). <i>Annals of Oncology</i> , 1998 , 9, 783-5	10.3	3
32	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , 2020 , 25, e1562-e1573	5.7	3
31	Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 957-963	3.5	3
30	A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. <i>Cancers</i> , 2021 , 13,	6.6	3
29	Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma. <i>Clinical Sarcoma Research</i> , 2018 , 8,	2.5	3
28	Review of past and present clinical cases with a view to future treatment options. <i>Future Oncology</i> , 2017 , 13, 11-28	3.6	2
27	Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. <i>British Journal of Cancer</i> , 2006 , 94, 1797-802	8.7	2
26	WNT/ECatenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities?. <i>Cancers</i> , 2021 , 13,	6.6	2
25	Current and future systemic treatment options for advanced soft-tissue sarcoma beyond anthracyclines and ifosfamide. <i>Cancer Translational Medicine</i> , 2017 , 3, 20	0.3	2
24	Risk-based treatment of non-rhabdomyosarcoma soft-tissue sarcoma in children. <i>Lancet Oncology</i> , 2020 , 21, 16-17	21.7	2
23	Prognostic Impact of MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study. <i>Cancers</i> , 2020 , 12,	6.6	2
22	Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?. <i>Future Oncology</i> , 2019 , 15, 17-23	3.6	2
21	Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists. <i>Journal of Surgical Oncology</i> , 2021 , 123, 12-23	2.8	2
20	Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 3861-3866	12.9	2
19	Pazopanib in the treatment of advanced solitary fibrous tumour - AuthorsReply. <i>Lancet Oncology</i> , 2019 , 20, e128	21.7	1

18	Indirect comparisons in cost-effectiveness analysis: are we being naïve?. <i>Clinical and Translational Oncology</i> , 2015 , 17, 85-6	3.6	1
17	Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. <i>Clinical Sarcoma Research</i> , 2016 , 6, 10	2.5	1
16	Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. <i>Oncotarget</i> , 2018 , 9, 17576-17588	3.3	1
15	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2021 , 92, 493-499	4.3	1
14	Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus. <i>Sarcoma</i> , 2019 , 2019, 4351308	3.1	1
13	A Novel Gene Fusion in Solitary Fibrous Tumor: A Case Report. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
12	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2173-2181	3.6	1
11	Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102259	14.4	1
10	Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102260	14.4	1
9	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101829	2.2	1
8	A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin. <i>Molecular Oncology</i> , 2021 , 15, 3691-3705	7.9	0
7	The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). <i>Clinical and Translational Oncology</i> , 2021 , 23, 2489-2496	3.6	0
6	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-ST5 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 2539-2552	6.1	0
5	Tumores del estroma gastrointestinal: breve actualización y consenso de la SEAP-SEOM sobre diagnóstico patológico y molecular. <i>Revista Espanola De Patologia</i> , 2017 , 50, 89-99	1.2	
4	Olaratumab-induced Biomarker Modulation in Sarcomas-Response. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 2094	6.1	
3	What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?. <i>Current Opinion in Oncology</i> , 2021 , 33, 329-335	4.2	
2	In Reply. <i>Oncologist</i> , 2019 , 24, e401-e402	5.7	
1	Rare solid and cystic presentation of hemangiopericytoma/ solitary fibrous tumor: A case report. <i>Current Problems in Cancer Case Reports</i> , 2022 , 6, 100149	0.3	

